The Rology teleradiology platform may improve access to top tier-imaging interpretation for stand-alone imaging centers, rural facilities and low-income patients.
The Food and Drug Administration (FDA) has granted 510(k) clearance for Rology, an on-demand teleradiology platform, which is currently being utilized in nine countries, and may bolster the capabilities of stand-alone imaging centers in the United States.
In addition to facilitating seamless acquisition of DICOM images and encryption of data, Rology said the artificial intelligence (AI)-enabled teleradiology platform matches the imaging review requests with top radiologists based upon subspeciality and availability. The company noted the Rology platform has access to a network of 306 reviewing radiologists.
Rology noted the teleradiology platform features a variety of FDA-cleared modules including an automatic image acquisition tool (Rology Connect), a workflow management system and DICOM viewer. The company added that 69 percent of scans with the Rology platform undergo peer review.
Rology emphasized that the zero-footprint platform improves access to top-tier imaging, noting that 39 percent of its scan requests originate from rural areas and 46 percent of its scans have been performed for low-income patients.
"This clearance doesn't just represent technological advancement, it symbolizes hope for countless medical providers, especially (stand-alone imaging centers) and the underserved public hospitals,” emphasized Moaaz Hossam, the chief business officer of Rology. “With this platform, they can now provide world-class radiology services, ensuring that every patient, irrespective of their location or the institution's size, receives top-notch care.”
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.